Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Blonanserin - Sumitomo Dainippon Pharma

Drug Profile

Blonanserin - Sumitomo Dainippon Pharma

Alternative Names: AD-5423; DSP-5423; DSP-5423P; Lonasen; LONASEN Tape

Latest Information Update: 14 Mar 2021

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Dainippon Sumitomo Pharma
  • Developer Bukwang Pharmaceutical; Dainippon Sumitomo Pharma; Nitto Denko; Sumitomo Dainippon Pharma
  • Class Antipsychotics; Piperazines; Piperidines
  • Mechanism of Action Dopamine D2 receptor antagonists; Dopamine D3 receptor antagonists; Serotonin 2A receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Schizophrenia

Most Recent Events

  • 01 May 2020 Preregistration for Schizophrenia (In children) in Japan (PO) (Sumitomo Dainippon Pharma pipeline, August 2020)
  • 22 Jul 2019 Sumitomo Dainippon Pharma announces intention to submit sNDA for Schizophrenia (In adolescents) in the first half of 2020 in Japan (PO)
  • 22 Jul 2019 Efficacy and adverse events data from a phase III trial in Schizophrenia (In adolescents) released by Sumitomo Dainippon Pharma
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with a username/password associated to your organization’s account.
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Federated access using single sign-on credentials.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top